Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited (RDY) generates a steady flow of news across product launches, clinical collaborations, financial results and regulatory updates. As a global pharmaceutical company headquartered in Hyderabad, India and active in APIs, generics, branded generics, biosimilars and OTC products, its announcements span multiple therapeutic areas and regions.
News coverage for Dr. Reddy's often includes product and portfolio updates, such as the first-to-market U.S. launch of over-the-counter olopatadine hydrochloride ophthalmic solution USP, 0.7%, the generic equivalent of Extra Strength Pataday Once Daily Relief. The company also reports on new brands and in-licensed assets in India and Emerging Markets, including vaccines and allergy immunotherapy products.
Investors and industry followers will find regular earnings and financial disclosures, where Dr. Reddy's presents consolidated IFRS results, segment performance for Global Generics and Pharmaceutical Services and Active Ingredients, and commentary on regional trends in North America, Europe, India and Emerging Markets. These releases provide insight into pricing dynamics, product launches and contributions from acquisitions such as nicotine replacement therapy portfolios.
Another important stream of news relates to biosimilar and biotech partnerships. Dr. Reddy's announces collaborations with companies like Alvotech, Shanghai Henlius Biotech and Bio-Thera Solutions for biosimilar candidates targeting denosumab, daratumumab, ustekinumab and golimumab, among others. Updates from Aurigene Oncology, its wholly owned subsidiary, cover early clinical data and platform presentations in oncology.
Regulatory and safety communications also appear in the news feed, including recalls of specific product lots and summaries of inspection outcomes at manufacturing and API facilities. For readers tracking RDY, this page offers a consolidated view of these developments, making it easier to follow how the company’s strategy, pipeline and operations evolve over time.
Dr. Reddy’s Laboratories announced the recognition of its largest manufacturing facility in Bachupally, Hyderabad, as part of the Global Lighthouse Network by the World Economic Forum. This achievement follows a four-year digitization journey and the launch of Project 'OpsNext,' which implemented six Industry 4.0 technologies. The facility has reported significant improvements, including 43% manufacturing cost reduction, 30% decrease in production lead time, and 41% reduction in energy consumption. Dr. Reddy's aims to enhance operational efficiency and meet ambitious ESG goals by 2030.
Dr. Reddy’s Laboratories has launched Lenalidomide Capsules, a generic version of REVLIMID®, in the U.S. Approved by the USFDA, this launch grants the company 180-day exclusivity for 2.5 mg and 20 mg strengths. The launch supports greater patient access and follows a settlement with Celgene, allowing Dr. Reddy’s to market limited amounts of the drug until January 31, 2026, when the volume limitation will be lifted. The capsules are available in various strengths, catering to diverse patient needs.
Dr. Reddy's Laboratories has announced a licensing agreement with Slayback Pharma for Brimonidine Tartrate Ophthalmic Solution 0.025%, an OTC eye drop designed to relieve redness. This agreement grants Dr. Reddy's exclusive rights outside the U.S. and positions them to enter a market valued at approximately $130 million as of June 2022. Slayback's ANDA for the product is currently under U.S. FDA review, marking a significant addition to Dr. Reddy's growing OTC eyecare portfolio.
Dr. Reddy’s Laboratories has launched Bortezomib for Injection 3.5 mg, a generic equivalent of Velcade®, in the U.S. market. This product is approved by the U.S. Food and Drug Administration. Velcade® and its generic versions garnered approximately $1.2 billion in U.S. sales for the year ending May 2022, according to IQVIA Health. The Bortezomib offering is available in a 3.5 mg per 10 mL single-dose vial for both subcutaneous and intravenous use.
Dr. Reddy’s Laboratories Ltd. has launched over-the-counter Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets in the U.S., the first store-brand equivalent of Allegra-D® 24 HR. Approved by the USFDA, this product aims to enhance the company's OTC portfolio for treating nasal and sinus congestion from colds or allergies. Allegra-D® had U.S. retail sales of approximately $45 million as of May 2022. The new tablets will be available in various pack sizes.
Dr. Reddy’s Laboratories has launched Fesoterodine Fumarate Extended-Release Tablets in the U.S., a generic equivalent to Toviaz®, approved by the U.S. FDA. The brand Toviaz® recorded U.S. sales of approximately $211 million for the year ending May 2022. The new product is available in 4 mg and 8 mg tablets, in bottles of 30. This therapeutic launch marks Dr. Reddy’s commitment to providing affordable medications in key international markets.
Aurigene Discovery Technologies has entered a collaboration with EQRx to accelerate drug development in oncology and immune-inflammatory diseases. Aurigene will lead discovery and pre-clinical efforts, while EQRx will handle clinical development and commercialization. This partnership aims to improve access to innovative medicines and enhance the global oncology franchise. With a history of developing 16 small molecule and peptide drug candidates, Aurigene leverages its expertise to drive meaningful savings for healthcare systems and deliver affordable treatments.
Dr. Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for approximately $5 million upfront, with potential contingent payments of $45 million. The acquisition includes the NDAs for Biorphen® and Rezipres® injections and aims to enhance Dr. Reddy’s institutional business in the U.S. market, where the total addressable market for these products is estimated at $174 million for the year ending April 2022. This move supports Dr. Reddy’s commitment to expanding affordable medications.
Dr. Reddy’s Laboratories Ltd. has launched Sorafenib Tablets, USP, a generic equivalent of Nexavar (sorafenib) in the U.S. market following approval from the U.S. Food and Drug Administration (USFDA). The 200 mg tablets are available in bottles of 120. CEO Marc Kikuchi emphasized the company's commitment to providing affordable medicines. This launch enhances Dr. Reddy's offerings in the oncology segment, expanding their portfolio aimed at improving patient access to critical treatments.
Dr. Reddy's Laboratories Ltd. has launched Pemetrexed for Injection in 100 mg and 500 mg single-dose vials, approved by the USFDA. This generic version is an equivalent to ALIMTA®, which generated approximately $1.24 billion in US sales for the twelve months ending March 2022. The introduction of this generic product expands Dr. Reddy's offerings in oncology and positions the company in a significant market segment, potentially benefiting its financial growth.